Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM) held on Tuesday, May 26, 2026.

All items on the agenda were approved, including:

• Approval of the statutory financial statements for the financial year ended December 31, 2025.
• Discharge to the current and former members of the Board of Directors and the statutory auditor in respect of the performance of their respective duties during the financial year ending on December 31, 2025.
• Reappointment of Mr. Ohad Hammer as a member of the Board of Directors for a term of one year.
• Reappointment of Mr. Tim Knotnerus as a member of the Board of Directors for a term of four years.

The voting result and all documents relating to the shareholders’ meeting are available on the Agomab investor relations website at https://ir.agomab.com/governance/shareholder-meetings.

Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinicalstage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences:

– ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled LungRestricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects’ on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, FL.
– H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Fireside chat on Tuesday, May 19, 2026 at 1:30 PM ET in New York, NY.
– 2026 RBC Capital Markets Global Healthcare Conference. Fireside chat on Wednesday, May 20, 2026 at 8:00 AM ET in New York, NY.
– JPM European Healthcare Symposium. Wednesday, June 10, 2026 in London, UK.
– BIO International Convention. Monday, June 22 – Thursday, June 25, 2026 in San Diego, CA.
– 2026 Leerink Partners Therapeutics Forum. One-on-one investor meetings on Wednesday, July 15, 2026 in Boston, MA.

— Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208
Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029
— Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase
2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD)
— On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic
Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026
— Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with
Ontunisertib in FSCD and from Phase 1b IPF Study Cohort with AGMB-447 Expected in Second Half of
2026